

## References

### I-123

1. Hole S, Pedersen A, Hansen S, Lundqvist J, Yde C, Lykkesfeldt A. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. *International Journal Of Oncology*. 2015;46(4):1481-1490.
2. Ellis M, Llombart-Cussac A, Robertson J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. *Journal Of Clinical Oncology*. 2015;33(32):3781-3787.
3. Cristofnili M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;425–39.
4. Musolino A, Campone M, Neven P et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2– breast cancer that had progressed during or after prior endocrine therapy. *Breast Cancer Research*. 2017;19-18.
5. MICROMEDEX®SOLUTIONS Compendia. 2020. Faslodex.
6. NCCN Drugs & Biologics Compendium™. Fulvestrant. 2020. National Comprehensive Cancer Network (NCCN).
7. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
8. Faslodex® (Fulvestrant) for injection [package insert]. Wilmington, DE, AstraZeneca Pharmaceuticals LP. Revised 11/2019.
9. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *Journal of Clinical Oncology*. 2017;35(25):2875-2887.
10. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im S, et al. Palbociclib combined with fulvestrant in premenopausal women with advanced breast

cancer and prior progression on endocrine therapy: PALOMA-3 results. *The Oncologist*. 2017;22:1028-1038.

11. Xu L, Yan N, Li Z, et al. A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis. *OncoTargets & Therapy*. 2018;11:8389-8398.
12. Quenel-Tueux N, Debled M, Rudewicz J, et al. Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. *British Journal of Cancer*. 2015;113(4):585-594.
13. Zhang T, Feng F, Zhao W, et al. Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: A network meta-analysis. *Cancer Management & Research*. 2018;10:5869-5880.